REPL Replimune Group, Inc.
$14.97
Replimune Group, Inc. (REPL) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.71 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.5% since its last earnings release on August 14, 2026.
Replimune Group Reported In-line with Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
2nd Quarter, Sep 2026
Nov 13
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($0.71)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$10.39
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Replimune Group, Inc.
Replimune Group, Inc. was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.
Sector
Healthcare
Industry
Biotechnology